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Abstract
Nitric oxide (NO) has multiple protective effects for regulating the cardiovascular and renal systems. The major functions include endothelium-
dependent relaxation, anti-inﬂammatory effects, as well as antihypertrophic and antithrombotic activities. Many of the activities mediated 
by NO are systematically antagonized by angiotensin-II (Ang II), a vasconstrictor peptide. Studies described in the review below have 
demonstrated that the balance between NO and Ang II activities rather than the absolute concentration of each molecule determines 
their effects on the physiology and pathophysiology of the cardiovascular and renal systems. NO donors have been used for years as 
therapeutic agents for a range of cardiovascular conditions including angina, myocardial infarction and for the reduction of arterial stiffness. 
An understanding of the mechanisms underlying the effects of these medications will enable the development of novel therapies to balance 
the effects of NO in the cardiovascular system.
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Introduction
Nitric oxide (NO) has multiple protective effects for regulating 
the cardiovascular and renal systems, including endothe-
lium-dependent relaxation, anti-inﬂammatory effects, anti-
thrombotic effects, and antihypertrophic activity (Figure 1).1
Many of these actions are systematically antagonized by 
the action of angiotensin-II (Ang II). Ang II is a vasoconstric-
tor peptide responsible for hypertension, decreased re-
gional blood ﬂow, impaired renal function, atherosclerosis, 
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and cardiac hypertrophy. NO primarily mediates vascular 
relaxation through stimulation of soluble guanylyl cyclase 
(sGC), leading to an increased production of cGMP which 
activates cGMP-dependent protein kinases, phospho-
diesterases and ion channels.2 NO can also act in a non-
cGMP-dependent process, leading to reversible, covalent 
modiﬁcation of proteins, for example by S-nitrosylation.3
NO interacts with superoxide (O2–) to generate peroxynitrite (ONOO–), which disrupts protein structures and mitochon-
dria.4 The balance between NO and Ang II activities rather 
than the absolute concentration of either molecule deter-
mines the effects on physiology and pathophysiology in mul-
tiple organ systems including the cardiovascular and renal 
systems.5
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Fig. 1. NO generated from the endothelium has protective effects on a variety of different cardiovascular processes (modiﬁed with permission 
from reference 1).
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NO has protective effects in the healthy 
endothelium
There is a complex feedback mechanism that regulates 
the balance of NO and Ang II (Figure 2).6  This balance 
is required for homeostasis in a number of organs and tis-
sues including the cardiovascular and renal systems.7,8 In 
the cardiovascular system, NO and Ang II interact in the 
endothelium where both molecules undergo the ﬁnal stages 
of synthesis. NO is synthesized by endothelial nitric oxide 
synthase (eNOS), a constitutive calcium- and calmodu-
lin-dependent enzyme that is upregulated in response to 
mechanical stimuli including shear stress and cyclic strain.9–11
Ang II is derived from angiotensin I (Ang I) by the angioten-
sin-II converting enzyme (ACE) which is also expressed in 
endothelial cells. NO can also downregulate the synthesis 
of ACE in the endothelium,12 thereby impacting the balance 
between NO and Ang II. The Ang II receptor AT1 medi-
ates the vasoconstrictive effects of Ang II as well as Ang 
II-induced growth in cardiovascular and renal tissues.13 NO 
also downregulates the level of the AT1 receptor in vascu-
lar smooth muscle cells which results in the decrease of 
Ang II activity.14,15 This feedback loop helps explain how NO 
can mediate vasodilation and decreased systemic blood 
pressure.
Ang II can stimulate mitochondrial dysfunction via a pro-
tein kinase C (PKC)-dependent pathway, resulting in the 
generation of reactive oxygen species (ROS). The PKC-
dependent pathway then activates NADPH oxidase, lead-
ing to the formation of peroxynitrite.  Doughan et al.16 used 
bovine aortic endothelial cells to study the effects of Ang II
on mitochondrial ROS and demonstrated that an increase 
in Ang II signiﬁcantly increases mitochondrial hydrogen 
peroxide production. The increase was blocked by incuba-
tion with the NOS inhibitor NG-nitro-L-arginine-methyl ester 
(L-NAME) and uric acid, a peroxynitrite scavenger, implicat-
ing peroxynitrite as a mediator of Ang II-induced mitochon-
drial dysfunction. The authors proposed a model in which 
Ang II stimulates NADPH oxidase via a PKC-dependent 
pathway, resulting in increased ROS production. Super-
oxide then reacts with NO to generate peroxynitrite, which 
damages respiratory complexes, leads to mitochondrial 
dysfunction, and increases hydrogen peroxide concentra-
tions. The increased hydrogen peroxide levels will further 
activate NADPH oxidase, resulting in increased supero-
xide, decreased NO availability, and ultimately, endothelial 
dysfunction.16
The balance between Ang II and NO also impacts the activ-
ity of membrane-bound NADPH oxidase, a major source of 
ROS in cardiovascular pathophysiology. Stimulation of Ang 
II activates a PKC-dependent pathway via AT1 which upreg-
ulates NADPH oxidases, resulting in an increase of super-
oxide which promotes eNOS uncoupling; uncoupled NOS 
preferentially generates superoxide instead of NO.17–19
 NO prevents upregulation of endothelin-1 (ET-1), a 
small potent vasoconstrictor20 that exhibits mitogenic activ-
ity in vascular smooth muscle cells, via the ET-1A recep-
tor, suggesting NO may have a role in the pathogenesis 
of disease, including atherosclerosis21 and hypertension.22
Incubation of smooth muscle cells with the NO donors S-
nitroso-N-acetylpenicillamine (SNAP) and sodium nitro-
prusside (SNP) resulted in attenuated ET-1-enhanced 
phosphorylation of ERK1/2, PKB, and Pyk2. The increase 
in NO inhibited the mitogenic and hypertrophic effects of 
ET-1 signaling. In contrast, inhibition of NO production by 
incubation with the NOS inhibitor L-NAME increased ET-1
enhanced phosphorylation.23 ET-1 also modulates both 
eNOS expression and NO production,24,25 affecting the rela-
tive activities of Ang II and NO. Ramzy and colleagues26
recently showed that ET-1 has a concentration-dependent 
effect on NO production in human saphenous vein endothe-
lial cells via PKC-dependent inhibition of eNOS expression, 
adding another level of complexity to the regulation of NO 
and vascular homeostasis. 
In pathologic conditions, long-term disruptions in NO syn-
thesis result in an increase in ACE production, which in turn 
increases the effects of Ang II in the rat aorta.27 Long-term 
inhibition of NO synthesis using the NOS inhibitor L-NAME 
increased ACE activity in the endothelium and resulted in 
oxidative stress which was visualized by increased aortic 
superoxide levels.27 Since treatment with antioxidant drugs 
did not affect the L-NAME-induced increase in systolic arte-
rial pressure but did prevent increases in vascular super-
oxide production and ACE activity, oxidative stress was 
implicated in the pathogenesis of vascular ACE activation 
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Fig. 2. Schematic representation of the pathophysiology of the interaction between NO and Ang II (modiﬁed from reference 5). Dotted 
lines represent inhibition, solid lines represent stimulation. NO=nitric oxide, NOS = nitric oxide synthase, AT1 = angiotensin receptor 1, 
ACE = angtiotensin converting enzyme, ET-1 = endothelin 1, aldo = aldosterone, ang II = angiotensin II, AT2  = angiotensin receptor 2, 
VSMC = vascular smooth muscle cell.
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in rats. These data suggest that ACE is upregulated by 
redox-sensitive mechanisms resulting from reduced levels 
of bioactive NO, demonstrating that NO levels may regulate 
vascular function in concert with local Ang II activities and/
or oxidative stress.27
HYPERTENSION
The physiological response to increasing vascular shear 
stress and cyclic strain which accompanies high blood 
pressure should be the upregulation of eNOS expression 
and the reduction of oxidative stress. However, in both 
humans and animal models, this is not always the case. 
Animal studies have helped to elucidate the mechanisms 
by which the balance between NO and Ang II is maintained. 
Experiments in genetic models of hypertension demon-
strated that spontaneously hypertensive rats (SHR) have 
increased eNOS expression, causing increased NO produc-
tion whereas Dahl-salt sensitive (DS) animals on high-salt 
diets have decreased eNOS mass, resulting in decreased 
NO production. Additional experiments in age-matched 
animals with similar levels of hypertension showed that 
animals with the ability to upregulate eNOS levels (SHR) 
have signiﬁcantly less end-organ damage than those who 
cannot upregulate eNOS activity (DS).28,29 Hypertensive 
SHR and DS rats manifest increased vascular production 
of superoxide. When SHR animals, which have the ability 
to upregulate eNOS, were exposed to increased levels of 
superoxide dismutase (SOD) by adenoviral infection, there 
was a decrease in blood pressure, suggesting that removal 
of superoxide increases the bioavailability of NO, resulting 
in an antihypertensive effect.30
Since an increase in the concentration of superoxide is 
in part responsible for the hypertensive effects in SHR rats, 
the next question was whether functional Ang II upregula-
tion is responsible for the increase in superoxide seen in DS 
rats.31 When hypertensive DS animals were fed angiotensin 
receptor blocker (ARB), there was a signiﬁcant decrease in 
superoxide production (visualized by ﬂuorescence micros-
copy), normalization of NO-mediated vascular relaxation 
but no decrease in blood pressure compared to hyperten-
sive animals. Therefore, reduction of oxidative stress by 
blocking Ang II receptor normalizes endothelial function, 
independent of blood pressure. This suggests that most 
of the superoxide generation results from an increase in 
Ang II activity, again illustrating the importance of the bal-
ance between NO and Ang II. These studies have important 
therapeutic implications regarding the role of Ang blockade 
in cardiovascular disease.
Role of NO and Ang II in atherosclerosis
Maintaining the balance between NO and Ang II is also 
important for preventing atherosclerosis. NO has a protec-
tive effect and can inhibit the initiation and progression of 
atherosclerotic plaque as well as act as an anti-inﬂamma-
tory mediator, independent of its vasodilation effects. Specif-
ically NO down-regulates the adhesion proteins VCAM-132
and P-selectin,33 inhibiting the ability of leukocytes to adhere 
to the endothelial wall. NO also inhibits platelet aggrega-
tion by blocking ﬁbrinogen binding with activated platelets 
which blocks thrombin receptor-activating phosphoinositide 
3-kinase activity.34 All three isoforms of NOS are expressed 
in atherosclerotic plaques.35 When mice null for eNOS were 
fed a Western-style diet they had signiﬁcantly more athero-
sclerotic lesions than those with wildtype levels of eNOS,36
illustrating the protective effect of NO on the formation of 
atherosclerotic lesions. Further experiments demonstrated 
that animals lacking the receptor for prostacyclin also have 
an increased rate of atherosclerotic progression.37 NO also 
has antiproliferative effects in vascular smooth muscle cells 
and can downregulate both AT1 receptors and the ACE 
enzyme. Finally, NO inhibits the expression of the proarth-
rogenic molecules MCP-1 and LOX-1. 
In contrast, ROS generated by Ang II-dependent activa-
tion of NADPH oxidase contributes to the pathogenesis of 
atherosclerosis by leading to endothelial dysfunction and 
upregulating proatherogenic molecules, including MCP-1 
and LOX-2.38
The renin-angiotensin system is also associated with 
inﬂammation and oxidative stress during atherosclerosis. 
Mice that are null for the AT2 receptor have increased ath-
erosclerotic disease progression compared to control ani-
mals.39 Later experiments demonstrated that LDL-receptor 
knockout mice overexpressing the AT2 receptor showed 
slower progression of atherosclerosis than LDL-null ani-
mals alone. In the LDL-null animals, NADPH oxidase is 
upregulated and eNOS expression is decreased but these 
changes are not present when AT2 is overexpressed. These 
results demonstrate that AT2 can regulate atherosclerosis, 
perhaps by modulating oxidative stress and the balance 
between NO and Ang II activities.40
Role of NO and Ang II in the kidney 
The balance between Ang II and NO is critical for normal 
kidney function and is responsible for renal vascular resis-
tance and ﬁltration rate. NO mediates renal vascular tone 
and blood pressure, glomerular and medullary hemody-
namics, and extracellular ﬂuid volume.  Experiments in 
hypertensive DS rats demonstrated that eNOS activity was 
decreased in the renal medulla when compared to normo-
tensive rats. The DS animals developed glomerular injury 
and severe tubulointerstitial disease and renal hypertrophy 
whereas hypertensive SHR rats had increased eNOS activ-
ity and showed no increase in tubulointerstitial disease and 
minimal renal hypertrophy. These experiments suggest that 
a decrease in eNOS activity is a maladaptive response that 
contributes to the maintenance of hypertension and pro-
gression of renal injury.41 Finally, genetic evidence also sup-
ports a protective effect of NO in renal function. End stage 
renal disease is signiﬁcantly more common in subjects with 
a speciﬁc polymorphism in the eNOS gene compared to 
healthy controls (P = 0.002)42, again   illustrating the protec-
tive effects of NO on renal pathophysiology.
In contrast to the protective effects of NO, Ang II decreases 
renal blood ﬂow and the glomerular ﬁltration rate and con-
stricts afferent and efferent arterioles in a dose-dependent 
manner. Studies show that in eNOS-null mice, there is an 
increase in Ang II sensitivity43 and that NO released from 
NOS activation contributes to control of afferent arteri-
oles.44 Finally, experiments show that the enhanced Ang 
II-dependent NADPH oxidase activation is likely caused by 
production of ROS.45 Increased ROS can decrease NO bio-
availability and result in increased endothelial dysfunction 
by shifting the balance of activity of both NO and Ang II. 
ANG II RECEPTORS IN THE KIDNEY
The Ang II receptor AT1 mediates constrictive effects in 
renal resistance arteries46 and experiments suggest that 
AT1 receptors mediate vasoconstriction in vessels control-
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ling medullary blood ﬂow, which are relatively insensitive to 
Ang II.47 AT2 receptors, however, appear to oppose AT1 func-
tion. Experiments with a speciﬁc AT2 antagonist, PD123319, 
increased basal medullary blood ﬂow, suggesting that AT2
activity opposes AT1 vasoconstriction. AT1 receptors also 
mediate NO release and play an important role in sympa-
thetic neurotransmission. In AT2 -/y receptor deﬁcient mice, 
there is an increased expression of AT1 receptors and a 
concomitant increase in NO found in the arterioles, show-
ing the effect AT1 has on NO concentrations.48
Finally, ROS play an important role in the pathophysi-
ology of the kidney. Long-term Ang II exposure leads to 
increased arterial pressure and renal vascular resistance 
in rats. Welch, et al.49 found there was also an increase in 
NADPH oxidase activity in the renal cortex and reduced 
SOD mRNA, resulting in an increased hydrogen peroxide 
concentration. The authors used Tempol, a SOD mimetic to 
block the effects of Ang II, suggesting a pathophysiological 
role for superoxide in this animal model.49
NO donors for treatment of cardiovascular 
disease
Endothelial dysfunction in both the cardiovascular and 
renal system is a candidate for treatment with NO donors 
to improve vasodilation, provide anti-inﬂammatory effects 
and antioxidant effects (Figure 3). Nitrates including nitro-
glycerin and nitroprusside are vasodilatory agents for 
acute cardiovascular conditions, including angina, myocar-
dial infarction and hypertensive emergencies. Nebivolol, a 
ȕ-blocker provides stimulation of the L-arginine/NO pathway 
and has been shown to reduce arterial stiffness.50 Novel 
hybrid NO donors are being developed and they include 
COX-inhibiting NO Donors (CINODs) which were designed 
in the hope of preventing the cardiovascular and gastro-
intestinal adverse events associated with NSAID use. An 
increased understanding of the mechanisms underlying the 
effects of NO and its relationship to endothelial dysfunction 
will enable the development of novel therapies to balance 
the effects of NO in the cardiovascular system.
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